Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter-still a dilemma?

Monika E. Hegi; Roger Stupp

doi:10.1093/neuonc/nov198

Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter-still a dilemma?

Monika E. Hegi^*, Roger Stupp

^*Corresponding author for this work

Neurological Surgery

Research output: Contribution to journal › Editorial › peer-review

65 Scopus citations

Original language	English (US)
Pages (from-to)	1425-1427
Number of pages	3
Journal	Neuro-oncology
Volume	17
Issue number	11
DOIs	https://doi.org/10.1093/neuonc/nov198
State	Published - Nov 2015

ASJC Scopus subject areas

Clinical Neurology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/neuonc/nov198

Cite this

@article{5849574fa50545e3bfe15a2235618b8d,

title = "Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter-still a dilemma?",

author = "Hegi, {Monika E.} and Roger Stupp",

year = "2015",

month = nov,

doi = "10.1093/neuonc/nov198",

language = "English (US)",

volume = "17",

pages = "1425--1427",

journal = "Neuro-oncology",

issn = "1522-8517",